GlassScriptPhysician profile
Jennifer A Allen
NPI 1043727829
$3,440.74
in general payments reported to CMS, 2019-2025
35 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $708 · 2023: $951 · 2024: $723 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Education: $23.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.86 |
| Education | $23.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $324.47 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $228.26 | 2022-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $205.22 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $184.48 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $177.61 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.45 | 2022-2025 | Jardiance |
| Medtronic, INC. | $149.95 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $142.04 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $137.14 | 2022-2025 | Korlym |
| Abbott Laboratories | $136.56 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $105.86 | 2023-2025 | Omnipod |
| Tolmar, INC. | $96.00 | 2023-2025 | Jatenzo |
| Antares Pharma, INC. | $87.61 | 2024-2025 | Xyosted |
| Kyowa Kirin, INC. | $76.29 | 2023-2025 | Crysvita |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $74.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $73.60 | 2022-2023 | Farxiga |
| Abbvie INC. | $60.18 | 2024-2025 | |
| Halozyme INC | $53.20 | 2023 | |
| Beta Bionics, INC. | $51.59 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $46.42 | 2024-2025 | |
| Chiesi USA, INC. | $44.23 | 2024-2025 | Myalept |
| Embecta Corp. | $42.99 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Mannkind Corporation | $42.30 | 2023 | Afrezza |
| Recordati_rare_diseases_inc. | $40.96 | 2025 | Isturisa |
| Ascensia Diabetes Care US INC. | $25.11 | 2022-2023 | |
| Cequr Corporation | $23.75 | 2023 | Cequr Simplicity |
| Sanofi US Services INC. | $23.70 | 2024 | |
| Ibsa Pharma INC. | $23.32 | 2025 | Licart, Flector, Tirosint |
| Amneal Pharmaceuticals LLC | $20.45 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $19.74 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $19.30 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $19.07 | 2023 | Strensiq |
| Amarin Pharma, INC. | $12.66 | 2022 | |
| Merck Sharp & Dohme LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.